WALTHAM, Mass. & MONTREAL– Ventus Therapeutics, Inc., a biopharmaceutical company leading a renaissance in the discovery and development of small molecule medicines by utilizing structural biology and a proprietary computational platform, today announced the promotion of Daniel Koerwer from Chief Business Officer to Chief Operating Officer. In this new role, in addition to corporate and business development, Mr. Koerwer will be responsible for several key areas, including intellectual property, human resources, company operations, and competitive intelligence.
“Since joining Ventus, Dan has been instrumental in the overall growth and strategy of our company,” said Marcelo Bigal, M.D., Ph.D., President and CEO at Ventus. “Dan’s promotion reflects the significant impact he has had across the breadth of Ventus’ operations to date. Dan is an established leader and I look forward to working with him in an expanded role to bring the operational excellence necessary to advance our disruptive ReSOLVE platform and our pipeline of innovative novel small molecule medicines.”
Mr. Koerwer has more than 20 years of experience in the biotech industry, with expertise in business development, corporate development, and commercial operations in the U.S. and abroad. Prior to joining Ventus, Mr. Koerwer was the Chief Business Officer at Arrakis Therapeutics and BIND Therapeutics. Previously, he served as President of Biogen’s biosimilars business and held leadership positions in the company’s corporate development, discovery research, and commercial operations groups. Mr. Koerwer received his M.B.A. from Harvard University and B.S. in biochemistry from Boston College.
“Ventus has grown exponentially in the last three years, culminating in the completion of multiple financing rounds with top-tier investors and the continued advancement of a promising pipeline and differentiated platform,” said Mr. Koerwer. “There is still plenty to do in bringing these small molecule therapies to patients, and we are well positioned to continue our upward trajectory.”
